Nirav Shah, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Loxo-Lilly
    Topic:
    Consulting/Advisory Board/Travel
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Miltenyi Biotec
    Topic:
    Consulting/Advisory Board/Travel
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Kite
    Topic:
    Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Incyte
    Topic:
    Consulting
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Janssen
    Topic:
    Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    BMS-Juno
    Topic:
    Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Seattle Genetics
    Topic:
    Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    TG Therapeutics
    Topic:
    Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Attribution:
    Self
    Type of financial relationship:
    Stock
    Ineligible company:
    Tundra Therapeutics
    Topic:
    Founder/Scientific Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
  • Type of financial relationship:
    Independent contractor
    Ineligible company:
    Epizyme
    Topic:
    Advisory Board
    Date added:
    03/19/2023
    Date updated:
    05/07/2024
Return to 2023 Annual Summit on Hematologic Cancers: Incorporation of Novel Therapies in Clinical Practice